- Home
- SNGX vs ENSC Comparison
SNGX vs ENSC Comparison
Compare SNGX & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- ENSC
- Stock Information
- Founded
- SNGX 1987
- ENSC 2003
- Country
- SNGX United States
- ENSC United States
- Employees
- SNGX N/A
- ENSC N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- ENSC Health Care
- Exchange
- SNGX Nasdaq
- ENSC Nasdaq
- Market Cap
- SNGX 9.6M
- ENSC 9.5M
- IPO Year
- SNGX 1987
- ENSC N/A
- Fundamental
- Price
- SNGX $3.16
- ENSC $6.07
- Analyst Decision
- SNGX
- ENSC
- Analyst Count
- SNGX 0
- ENSC 0
- Target Price
- SNGX N/A
- ENSC N/A
- AVG Volume (30 Days)
- SNGX 46.1K
- ENSC 154.9K
- Earning Date
- SNGX 11-08-2024
- ENSC 11-12-2024
- Dividend Yield
- SNGX N/A
- ENSC N/A
- EPS Growth
- SNGX N/A
- ENSC N/A
- EPS
- SNGX N/A
- ENSC N/A
- Revenue
- SNGX $364,183.00
- ENSC $4,421,404.00
- Revenue This Year
- SNGX N/A
- ENSC N/A
- Revenue Next Year
- SNGX $76.64
- ENSC N/A
- P/E Ratio
- SNGX N/A
- ENSC N/A
- Revenue Growth
- SNGX N/A
- ENSC 40.41
- 52 Week Low
- SNGX $1.83
- ENSC $2.12
- 52 Week High
- SNGX $19.20
- ENSC $30.90
- Technical
- Relative Strength Index (RSI)
- SNGX 41.70
- ENSC 42.77
- Support Level
- SNGX $2.93
- ENSC $5.34
- Resistance Level
- SNGX $3.35
- ENSC $8.27
- Average True Range (ATR)
- SNGX 0.19
- ENSC 1.06
- MACD
- SNGX -0.01
- ENSC -0.24
- Stochastic Oscillator
- SNGX 37.10
- ENSC 18.43
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.